AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)
  • Load image into Gallery viewer, AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)

AVASTIN/MVASI/ ZIRABEV/BAMBEVI (Bevacizumab)

Vendor
ROCHE/AMGEN/PFIZER/APOTEX
Regular price
$769.99 USD
Sale price
$769.99 USD
Regular price
Sold out
Unit price
per 
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

AVASTIN/MVASI/ZIRABEV/BAMBEVI (Bevacizumab)
Antineoplastic; Monoclonal Antibody; Vascular Endothelial Growth Factor Inhibitor

AVASTIN and biosimilars MVASI/ZIRABEV/BAMBEVI are vascular endothelial growth factor-specific angiogenesis inhibitors indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, and glioblastoma.

ALERT: WARNING
Gastrointestinal perforations have occurred with AVASTIN/MVASI/ZIRABEV/BAMBEVI (Bevacizumab). Risk of wound healing and surgical complications is increased with Bevacizumab, Avastin.  Discontinue Bevacizumab in patients with wound dehiscence.  Discontinue at least 28 days prior to elective surgery.  Do not initiate Bevacizumab for at least 28 days after surgery and until the surgical wound is fully healed.
Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, central nervous systems (CNS) hemorrhage, epistaxis, and vaginal bleeding occurred up to five-fold more frequently in patients receiving Bevecizumab.

What is a biosimilar biologic drug?

Manufacturers have found cost-efficient ways to recreate the molecules used in the original or “reference” biologic drug.  Biosimilars are highly “similar” to a reference biological drug despite differing in their chemical composition.  

The FDA approval of biosimilar drugs is based on a totality of evidence which is used by regulators in the approval of reference and biological drugs.  The FDA uses the same approach in evaluating biosimilars to confirm that there are no clinically meaningful differences in safety and efficacy between the reference biologic drug and the biosimilar.  The rigorous standard for authorization means that you can have confidence knowing that the quality, safety, and efficacy of a biosimilar is the same as any other biologic drug.

AVASTIN is a biologic
MVASI is a biosimilar to AVASTIN (Bevacizumab)
ZIRABEV is a biosimilar to AVASTIN (Bevacizumab)
BAMBEVI is a biosimilar to AVASTIN (Bevacizumab)

What is the difference between the brands?

ZIRABEV and BAMBEVI are biosimilars to the reference drug product, AVASTIN, which works by inhibiting the formation of new blood vessels (angiogenesis) by specifically recognizing and binding to vascular endothelial growth factor (VEGF) protein.

How does this medication work? 

AVASTIN/MVASI/ZIRABEV/BAMBEVI (Bevacizumab) is a recombinant, humanized monoclonal antibody which bind and neutralizes vascular endothelial growth factor (VEGF) which prevents the proliferation and formation of new blood vessels.  The inhibition of microvascular growth is believed to retards cancerous growth.

How should I take this medication? 

IV: Inject 5 mg/kg or 10 mg/kg by intravenous infusion every 2 weeks when used in combination with another chemotherapy agent until disease progression or unacceptable toxicity.  

Note: Do not administer as an intravenous push or bolus.

How to Take: Administer the first infusion over 90 minutes, the length of the infusion can be reduced to 60 and 30 minutes on subsequent treatments if tolerated.  Medical care staff must always closely monitor the patient for any signs/symptoms of an infusion reaction. 

What should I watch for while using this medication? 

AVASTIN/MVASI/ZIRABEV/BAMBEVI (Bevacizumab) can cause serious adverse effects which may require temporarily suspending or discontinuing the medication entirely.  Discontinue Bevacizumab if you experience any one of the following: fistula, thromboembolic event (i.e. myocardial and/or cerebral infarction), hypertension, hypertensive crisis, hypertensive encephalopathy, and nephrotic syndrome. Immediately contact your doctor if you experience any unusual bleeding, high fever, rigors, sudden onset of worsening neurological function, or persistent or severe abdominal pain, severe constipation, or vomiting.

What if I miss a dose?

Bevacizumab is administered in a hospital or cancer treatment center by a nurse or other licensed healthcare professional. Contact your physician immediately if you miss an appointment for your injection.

How should I store this medication?

Store diluted solution refrigerated at 2°C to 8°C (36°F to 46°F) for up to 8 hours. No incompatibilities between Avastin and polyvinylchloride or polyolefin bags have been observed.

For single use only. The vials should be used once only and any remaining contents should be discarded.

What are the possible side effects of using this medication?

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, and exfoliative dermatitis.

Note this is not a complete list of side effects for AVASTIN/MVASI/ZIRABEV/BAMBEVI (Bevacizumab), only common ones.